Lexaria Bioscience Corp. Operating Income

Quick Answer

Lexaria Bioscience Corp. reported Operating Income of -$11.88 million for fiscal year 2025.

Lexaria Bioscience Corp. Operating Income — Annual History

Fiscal Year Operating Income YoY Change
2025 -$11.88M -106.5%
2024 -$5.75M +12.0%
2023 -$6.53M +1.3%
2022 -$6.62M -16.4%
2021 -$5.69M -345.2%
2016 -$1.28M +35.6%
2015 -$1.98M -27.2%
2014 -$1.56M

Quarterly Operating Income

Quarter Ending Operating Income YoY QoQ
November 30, 2025 -$1.57M +41.5% +58.0%
May 31, 2025 -$3.75M -115.2% -36.3%
February 28, 2025 -$2.75M -311.8% -2.2%
November 30, 2024 -$2.69M -136.2% -54.4%
May 31, 2024 -$1.74M +27.4% -160.9%
February 29, 2024 -$668.0K +49.5% +41.4%
November 30, 2023 -$1.14M +32.8% +52.6%
May 31, 2023 -$2.40M +0.7% -81.4%
  • Lexaria Bioscience Corp. showed a decrease of -106.5% in Operating Income compared to the prior fiscal year.
  • Over the 2014–2025 period, Lexaria Bioscience Corp.’s operating income has declined by 661.9% (from -$1.56 million to -$11.88 million).
  • The most recent figure is from Lexaria Bioscience Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on November 28, 2025.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment